Ossigeno C.I.O. (Oxygen)

Oxygen delivered by Ossigeno C.I.O. diffuses across the alveolar membrane into the bloodstream, raising the partial pressure of oxygen in arterial blood. This increases hemoglobin saturation, allowing more oxygen to be transported to cells where it participates in cellular respiration and ATP production, essential for organ function.

The prescribed dose of Ossigeno C.I.O. is determined by the treating clinician based on the patient’s oxygen saturation, underlying condition, and clinical response. Dosage is expressed as flow rate (e.g., liters per minute) and concentration, and should be set according to medical guidance.

Oxygen therapy is generally considered safe during pregnancy and lactation when medically indicated, as it does not cross the placenta in harmful amounts. However, the prescribing physician should evaluate the risk‑benefit ratio for each individual, and the therapy should be administered under professional supervision.

To order Ossigeno C.I.O., submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Ossigeno C.I.O. is a medical‑grade oxygen gas sourced from the EU, meeting strict quality standards. Compared with lower‑purity oxygen sources, it offers consistent concentration and purity, reducing the risk of contaminants. Its compatibility with standard delivery devices makes it comparable to other high‑purity medical oxygen products while adhering to international regulatory requirements.

Ossigeno C.I.O. should be stored at ambient temperature, preferably below 25 °C, in its original cylinder or container. Keep it in a well‑ventilated area away from heat sources, direct sunlight, and flammable materials. Ensure cylinders are secured upright to prevent tipping and protect valve connections from damage.

Ossigeno C.I.O. is administered via inhalation using appropriate delivery systems such as nasal cannulae, simple face masks, or non‑rebreather masks. The flow rate and delivery device are selected by the healthcare professional based on the patient’s oxygen requirement and clinical condition.

Serious risks include pulmonary oxygen toxicity, which can lead to lung injury if high concentrations are used for prolonged periods, and fire or explosion hazards when oxygen contacts flammable substances. Patients should be monitored for signs of hyperoxia, and strict safety protocols must be followed to prevent ignition sources near the gas.

Patients with known hypersensitivity to oxygen delivery equipment, those with uncontrolled carbon dioxide retention without proper monitoring, or individuals in environments where fire risk cannot be adequately controlled should not receive Ossigeno C.I.O. without careful medical assessment and appropriate safety measures.